Relative recovery of haematopoietic stem cell products after cryogenic storage of up to 19 years

Fernyhough, Liam; Buchan, V A; McArthur, L T; Hock, Barry D.

doi:10.1038/bmt.2012.97

Cited by 28 publications

(24 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Long-term storage (> 60 months) of PBSCs in vapor phase nitrogen after controlled rate freezing also did not have a negative effect on hematopoietic recovery [79]. However, in another study, total nucleated cell count, CD34+ cell count, and cell viability for cells from peripheral blood or bone marrow cryopreserved for 11–19 years was found to decrease with time [82]. …”

Section: Additional Considerationsmentioning

confidence: 99%

Cryopreservation of Hematopoietic Stem Cells: Emerging Assays, Cryoprotectant Agents, and Technology to Improve Outcomes

Hornberger

McKenna

et al. 2019

Transfus Med Hemother

View full text Add to dashboard Cite

Hematopoietic stem cell (HSC) therapy is widely used to treat a growing number of hematological and non-hematological diseases. Cryopreservation of HSCs allows for cells to be transported from the site of processing to the site of clinical use, creates a larger window of time in which cells can be administered to patients, and allows sufficient time for quality control and regulatory testing. Currently, HSCs and other cell therapies conform to the same cryopreservation techniques as cells used for research purposes: cells are cryopreserved in dimethyl sulfoxide (DMSO) at a slow cooling rate. As a result, HSC therapy can result in numerous adverse symptoms in patients due to the infusion of DMSO. Efforts are being made to improve the cryopreservation of HSCs for clinical use. This review discusses advances in the cryopreservation of HSCs from 2007 to the present. The preclinical development of new cryoprotectants and new technology to eliminate cryoprotectants after thawing are discussed in detail. Additional cryopreservation considerations are included, such as cooling rate, storage temperature, and cell concentration. Preclinical cell assessment and quality control are discussed, as well as clinical studies from the past decade that focus on new cryopreservation protocols to improve patient outcomes.

show abstract

Section: Additional Considerationsmentioning

confidence: 99%

Cryopreservation of Hematopoietic Stem Cells: Emerging Assays, Cryoprotectant Agents, and Technology to Improve Outcomes

Hornberger

McKenna

et al. 2019

Transfus Med Hemother

View full text Add to dashboard Cite

show abstract

“…Besides the relative long-term period of evaluation comparable to other studies [910], our study has three advantages over previous studies assessing CBU quality [910111213]. First, while many previous studies compared groups of CBUs that had been stored for a specific duration, we planned to aliquot a single unit into 21 capillaries that can be tested over time.…”

Section: Discussionmentioning

confidence: 98%

Long-Term Quality Control Program Plan for Cord Blood Banks in Korea: A Pilot Study for Cryopreservation Stability

et al. 2017

View full text Add to dashboard Cite

Background: Maintaining the quality of cryopreserved cord blood is crucial. In this pilot study, we describe the results of the internal quality control program for a cord blood bank thus far.Methods: Donated cord blood units unsuitable for transplantation were selected for internal quality control once a month. One unit of cord blood, aliquoted into 21 capillaries, was cryopreserved and thawed annually to analyze the total nucleated cell count, CD34+ cell count, cell viability test, and colony-forming units assay.Results: No significant differences in the variables (total nucleated cell count, cell viability, CD34 + cell count) were observed between samples cryopreserved for one and two years. Upon comparing the variables before cryopreservation and post thawing with the capillaries of one year of storage, cell viability and CD34 + cell counts decreased significantly. The use of cord blood samples in capillaries, which can be easily stored for a long period, was similar to the methods used for testing segments attached to the cord blood unit. Conclusions:The results of this study may be useful for determining the period during which the quality of cryopreserved cord blood units used for transplantation is maintained.

show abstract

“…La dé cision validé e en RCP : contamination microbiologique : discussion en RCP avec avis du comité de lutte contre les infections nosocomiales : duré e de stockage supé rieure à 15 ans en prenant en compte le rapport bé né fice/risque pour le malade [1,2].…”

Section: Destruction Des Produits Cellulaires Alloge´niques [Csh Fraunclassified

Modalités de conservation et de destruction des produits cellulaires cryopréservés : recommandations de la SFGM-TC

Calmels

Boulanger²,

Baudoux³

et al. 2014

Pathologie Biologie

View full text Add to dashboard Cite

Relative recovery of haematopoietic stem cell products after cryogenic storage of up to 19 years

Cited by 28 publications

References 22 publications

Cryopreservation of Hematopoietic Stem Cells: Emerging Assays, Cryoprotectant Agents, and Technology to Improve Outcomes

Cryopreservation of Hematopoietic Stem Cells: Emerging Assays, Cryoprotectant Agents, and Technology to Improve Outcomes

Long-Term Quality Control Program Plan for Cord Blood Banks in Korea: A Pilot Study for Cryopreservation Stability

Modalités de conservation et de destruction des produits cellulaires cryopréservés : recommandations de la SFGM-TC

Contact Info

Product

Resources

About